PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
mation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10589866	
NIEGONA TIGN DIGGI GGUDE	Filing Date		2006-09-19	
INFORMATION DISCLOSURE	First Named Inventor	BERG	COVIER	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1645	
(Not for Submission under or of K 1.55)	Examiner Name	DEVI	-	
	Attorney Docket Numb	er	27637U	

U.S.PATENTS Remove									
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	,Columns,Lines wher ant Passages or Rele s Appear	
	1								
If you wis	h to ad	ու d additional U.S. Pate	nt citatio	n information	olease click the	Add button.	l	Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publication Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	,Columns,Lines wher ant Passages or Rele s Appear	
	1								
If you wis	h to ad	d additional U.S. Pub	lished Ap	plication citati	on information	please click the Ad	d button		
			7	FOREIGN PA	TENT DOCUM	IENTS		Remove	
Examiner Initial*		Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or F	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	*								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials* Cite No Cite No Cite No Capital Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589866
Filing Date		2006-09-19
First Named Inventor BERC		COVIER
Art Unit		1645
Examiner Name	DEVI	
Attorney Docket Number		27637U

/S.D./	1	NIGOU, et al., "Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor", The Journal of Immunology, vol. 166, pgs. 7477-7485, (2001).	
/S.D./	2	NIGOU, et al., "Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response", Microbes and Infection, vol. 4, pgs. 945-953, (2002).	
/S.D./	3	OLSON, et al., "Design and Synthesis of a Protein β-Turn Mimetic", J. Am. Chem. Soc., vol. 112, pgs. 323-333, (1990).	
/S.D./	4	PINCUS, et al., "Peptides That Mimic the Group B Streptococcal Type III Capsular Polysaccharide Antigen", The Journal of Immunology, vol. 160, pgs. 293-298, (1998).	
/S.D./	5	PRINZIS, et al., "Structure and anitgenicity of lipoarabinomannan from Mycobacterium bovis BCG", Journal of General Microbiology, vol. 139, pgs. 2649-2658, (1993).	
/S.D./	6	QUESNIAUX, et al., "Toll-Like Receptor 2 (TLR2)-Dependent-Positive and TLR2-Independent-Negative Regulation of Proinflammatory Cytokines by Mycobacterial Lipomannans", The Journal of Immunology, vol. 172, pgs. 4425-4434, (2004).	
/S.D./	7	SCHLESINGER, et al., "Binding of the Terminal Mannosyl Units of Lipoarabinomannan from a Virulent Strain of Mycobacterium Tuberculosis to Human Macrophages", Journal of Immunology, vol. 152, pgs. 4070-4079, (1994).	
/S.D./	8	SETHI, et al., "Contraction-Mediated Pinocytosis of RGD-Peptide By Dermal Fibroblasts: Inhibition of Matrix Attachment Blocks Contraction and Disrupts Microfilament Organisation", Cell Motility and Cytoskeleton, vol. 52, pgs. 231-241, (2002).	
/S.D./	9	SHIRAKAWA, et al., "The Inverse Association Between Tuberculin Responses and Atopic Disorder", Science, vol. 275, pgs. 77-79, (1997).	
/S.D./	10	SHIRTCLIFFE, et al., "An inverse correlation between estimated tuberculosis notification rates and asthma symptoms", Respirology, vol. 7, pgs. 153-155, (2002).	
/S.D./	11	SINGH, et al., "Advances in Vaccine Adjuvants for Infectious Diseases", Current HIV Research, vol. 1, pgs. 309-320, (2003).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589866
Filing Date		2006-09-19
First Named Inventor BERC		COVIER
Art Unit		1645
Examiner Name	DEVI	
Attorney Docket Number		27637U

/S.D./	12	SMITH, et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage", Methods in Enzymology, vol. 217, pgs. 228-257, (1993).	
/S.D./	13	STERN, et al., "Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library", FASEB J., vol. 11, pgs. 147-153, (1997).	
/S.D./	14	TEMKIN, et al., "Tumor necrosis factors in a murine model of allergic peritonitis: effects on eosinophil accumulation and inflammatory mediators' release", Cytokine, vol. 24, pgs. 74-80, (2003).	
/S.D./	15	TIBBETTS, et al., "Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function", Peptides, vol. 21, pgs. 1161-1167, (2000).	
/S.D./	16	VALADON, et al., "Enhancement of ELISAs for screening peptides in epitope phage display libraries", Journal of Immunological Methods, vol. 197, pgs. 171-179, (1996).	
/S.D./	17	VON MUTIUS, et al., "International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema", Thorax, vol. 55, pgs. 449-453, (2000).	
/S.D./	18	VYAS, et al., "Structural basis of peptide-carbohydrate mimicry in an antibody-combining site", PNAS, vol. 100, no. 25, pgs. 15023-15028, (2003).	
/S.D./	19	WANG, et al., "Epitope Identification and Discovery Using Phage Display Libraries: Applications in Vaccine Development and Diagnostics", Current Drug Targets, vol. 5, pgs. 1-15, (2004).	
/S.D./	20	WU, et al., "The Pharmacological Actions of Nicotine on the Gastrointestinal Tract", Journal of Pharmacological Sciences, vol. 94, pgs. 348-358, (2004).	
/S.D./	21	YOSHIMURA, et al., "Role of NFκB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", Eur. J. Immunol., vol. 31, pgs. 1883-1893, (2001).	
/S.D./	22	ZABROCKI, et al., "Conformational Mimicry. 1. 1,5-Disubstituted Tetrazole Ring as a Surrogate for the Cis Amide Bond", J. Am. Chem. Soc., vol. 110, pgs. 5875-5880, (1988).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589866
Filing Date		2006-09-19
First Named Inventor BERC		COVIER
Art Unit		1645
Examiner Name	DEVI	
Attorney Docket Number		27637U

/S.D./	23	ZECHEL, et al., "Synthetic glucagon antagonists and partial agonists", Int. J. Peptide Protein Res., vol. 38, pgs. 131-138, (1991).						
/S.D./	24	ZUANY-AMORIM, et al., "Suppression of airway eosinophilia by killed mycobacerium vaccae-induced allergen-specific regulatory T-cells", Nature Medicine, vol. 8, no. 6, pgs. 625-629, (2002).						
/S.D./	25	Enzy	MIYAKK, et al., "1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Angiotensin: Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives", J. Takeda Res. Labs., vol. 43, pgs. 53-76, (1984).					
/S.D./	/S.D./ DELUCA, et al., "Parenteral Drug-Delivery Systems", Pharmaceutics and Pharmacy Practice, ch. 8, pgs. 238-250, J.B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., (1982).							
/S.D./	27	TRIS	TRISSEL, "Intravenous Infusion Solutions", ASHP Handbook on Injectable Drugs, 4th ed., pgs. 622-630, (1986).					
/S.D./ 28 ENSHELL-SEIJFFERS, et al., "Phage Display Selection and Analysis of Ab-Binding Epitopes", Current Protocols in Immunology, vol. 2, pgs. 9.8.1-9.8.27, (2002).								
If you wis	h to a	dd add	ditional non-patent literature document citation information p	lease click the Add b	outton Add			
			EXAMINER SIGNATURE					
Examiner	Examiner Signature /S. Devi/			Date Considered	12/07/2010			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Standard S ⁻¹ 4 Kind of do	T.3). ³ l cument	or Japa by the	TO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office anese patent documents, the indication of the year of the reign of the Empappropriate symbols as indicated on the document under WIPO Standard on is attached.	eror must precede the ser	ial number of the patent doc	ument.		